SOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering,.

SOUTH SAN FRANCISCO, Calif., May 26, 2020 -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering,.

We can readily understand why investors are attracted to unprofitable companies. For example, although...

RAPT Therapeutics, Inc. (RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the promotions of Paul Kassner, Ph.D., to Senior Vice President of Quantitative and Computational Biology and Lisa Moore, Ph.D., to Vice President of Business Development and Strategy. “Both Paul and Lisa continue to make incredible contributions to RAPT’s success in setting and implementing strategic business and scientific plans,” said Brian Wong, M.D., Ph.D., President and CEO of RAPT Therapeutics.

RAPT Therapeutics, Inc. (RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the pricing of its underwritten public offering of 2,500,000 shares of common stock at a public offering price of $30.00 per share. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 375,000 shares of common stock at the public offering price, less the underwriting discount. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by RAPT, are expected to be $75.0 million, excluding any exercise of the underwriters’ option to purchase additional shares.

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2019 -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering,.

RAPT Therapeutics, Inc. (RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that it has commenced an underwritten public offering of 2,000,000 shares of its common stock. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 300,000 shares of common stock sold in connection with the offering. BMO Capital Markets, Wells Fargo Securities, UBS Investment Bank and Cantor Fitzgerald & Co. are acting as joint book-running managers for the offering.

SOUTH SAN FRANCISCO, Calif., May 15, 2020 -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering,.

SOUTH SAN FRANCISCO, Calif., May 12, 2020 -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering,.

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2020 -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering,.

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, and Hanmi Pharmaceutical Co., LTD today announced a license and collaboration agreement for FLX475 in Asia. FLX475 is an oral, small molecule CCR4 antagonist in development for the treatment of multiple cancers.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 3) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares ...

RAPT Therapeutics, Inc. (RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the appointment of Rodney Young as chief financial officer effective December 2, 2019. “As a newly public company, we are thrilled to welcome Rodney to RAPT,” said Brian Wong, M.D., Ph.D., president and CEO of RAPT Therapeutics. Mr. Young brings more than 30 years of executive management and corporate finance experience.

Today is shaping up negative for RAPT Therapeutics, Inc. (NASDAQ:RAPT) shareholders, with the analysts delivering a...

RAPT Therapeutics, Inc. (RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that the Company will be added to the Russell 2000® and Russell Microcap® Indices as a part of the Russell quarterly update, effective December 23, 2019. The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity market, while membership in the Russell Microcap® Index measures the performance of the micro-cap segment. Membership in the Russell 2000 and Microcap Indices also provides automatic inclusion in the appropriate growth and value style indices.

RAPT Therapeutics, Inc. (RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Mary Ann Gray, Ph.D., President of Gray Strategic Advisors, LLC, has joined its Board of Directors. “We are pleased to welcome Mary Ann to our Board, as she brings a wealth of scientific and financial expertise from her time investing in and covering biotech companies, as well as broad leadership experience guiding companies as they develop key therapeutics with a wide range of pharmacological applications,” said Brian Wong, M.D., Ph.D., President and CEO of RAPT Therapeutics.

RAPT Therapeutics, Inc. (NASDAQ:RAPT) missed earnings with its latest first-quarter results, disappointing...

SOUTH SAN FRANCISCO, Calif., May 14, 2020 -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering,.

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

SOUTH SAN FRANCISCO, Calif., March 30, 2020 -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering,.